Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood pressure procedure spare the kidneys?

NCT ID NCT07786636

Knowledge-focused Sponsor: Rede Optimus Hospitalar SA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study looks at how renal denervation, a minimally invasive procedure for hard-to-treat high blood pressure, affects kidney function shortly after and up to a year later. Researchers will measure kidney function and analyze blood and urine samples from 50 adults with resistant hypertension. The goal is to see if the procedure causes changes in the kidneys and whether those changes relate to better kidney health over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Renal denervation procedure
What this could lead to
If successful, this could clarify how renal denervation impacts kidney health, potentially guiding better use of the procedure for resistant hypertension.
What could go wrong
This is an observational study with a small sample size, so findings may not apply broadly. The procedure itself carries risks, and the study does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years * eGFR \>30 ml/min/1.73m2 (CKD stages 3b and less severe) * Informed consent for study participation provided by the patient or the legal guardian * Patient information and consent to the processing of personal data * Stable therapy in the previous three months * All patients undergoing RDN for clinical indications Exclusion Criteria: * Patients in emergency situations * Turbid urine sample on admission * Visible haematuria in the urine sample on admission * Pregnancy * Allergy to contrast media (visipaque, omnipaque, iohexol) * Any problem, which, in the investigator's opinion, might jeopardize the participant's compliance with the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal denervation therapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal denervation therapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.